|
GSK runs to PhIII with upbeat data on drug for severe asthma
FierceBiotech GlaxoSmithKline ($GSK) generated positive results from a mid-stage trial for its experimental drug in patients with an uncommon form of asthma, giving the London drug giant confidence in advancing the program to Phase III development before the end of … |
View full post on asthma – Google News